PREDICTING CARDIOVASCULAR RISK USING COMMON UTILIZATION MANAGEMENT CRITERIA FOR PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS IN COMMERCIALLY INSURED PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

Machaon Bonafede,Stefan DiMario,Jeetvan Patel,Barbara Johnson,David J. Harrison

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2018）

引用 0|浏览24

暂无评分

摘要

A growing body of literature suggests significant difficulty in gaining access and reimbursement for proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), which are indicated for additional lowering of low density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic

查看译文

关键词

Cholesterol-lowering,Atherosclerotic Cardiovascular Risk

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要